Hetero Drugs Limited is one of India’s generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Hetero’s business includes APIs, generics, biosimilars, custompharmaceutical services, and branded generics. Hetero has 36 manufacturing facilities located worldwide. 300 plusproducts encompassing major therapeutic categories such as HIV/AIDS, Oncology, Cardiovascular, Neurology, Hepatitis, Nephrology, Urology, Diabetes, Ophthalmology, Hepatology, and Immunology. Hetero has a presence in over 126 countries.
Operations
Hetero group employs over 21,000 people. Hetero is a player in the active pharmaceutical ingredients market and finished dosages. It has marketing presence in over 127 countries. Hetero has supplied antiretroviral drugs to patients across more than 100 countries globally. Today, Oseltamivir, sold under its brand nameFluvir, is also indicated for A virus, also known as swine flu. Hetero also produces hepatitis C antivirals such as Sofovir and Ledifos.
Company structure
Hetero Drugs Limited is the parent company in the Hetero group of companies and other companies which are part of the group are Hetero Labs, Hetero Research Foundation, Genx Laboratories and also foreign subsidiaries such as Camber Pharma Inc., in USA, Hetero Europe in Europe, and Richmond Labs in Argentina. The group is also investing in the wind power industry with a goal to reach 1000 megawatts by 2017.
In 2009, as the swine flu outbreak was spreading across the globe and various health organizations and government agencies were piling up stocks of Oseltamivir as precautionary measures, Hetero supplied generic Oseltamivir under its brand name Fluvir. Hetero delivered 10 million doses of Oseltamivir to the Indian government in 2009, and shipped about 80 million doses to over 60 countries. Hetero received its second order from Indian government to supply another 10 million doses of Oseltamivir later in 2009.
The company has launched the generic version of experimental COVID-19 drug Remdesivir under brand name Covifor after acquiring license from Gilead Sciences and obtaining approval from CDSCO, the Indian drug control authority.
